MAPK7 and lung carcinoma: This is in line with our in vitro data, demonstrating a significant reduction of the proliferation/viability of the tested lung cancer cell lines (NCI-H226, NCI-H2122, and NCI-H1650) after ERK5 inhibition (Fig. 4).